Conference Presentation Details - Overview

View all Online CME

Continuing Education Information

Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Oncology Consultations Live: Challenging Questions in Lymphomas

Release Date: July 6, 2010| Expiration Date: July 6, 2011
2 AMA PRA Category 1 Credit(s)| Jun 5, 2010, Chicago, IL

Learning Objectives

At the conclusion of this educational activity, you should be able to:

  • Outline differential diagnosis criteria relating to B-cell and T-cell lymphomas and the different subtypes of peripheral T-cell lymphomas
  • Evaluate current treatment options for patients with B-cell and T-cell lymphomas based on patient and tumor characteristics and prior therapies
  • Assess treatment optimization strategies with respect to duration of therapy and maintenance therapy in patients with follicular lymphoma
  • Appraise current challenges in the use of transplantation strategies in terms of patient selection, depth of response achieved, and emerging novel agents

Choose a Participation Option

Take this activity for credit

To claim credit for this activity you must:

  • Take the Pretest
  • Participate in the Activity
  • Take the Posttest
  • Take the Evaluation
  • Claim your Credit Amount & Certificate Type
Just show me the activity

If you do not wish to claim credit:

You may bypass all CE information, tests and evaluations and go straight to the activity.

You may not request credit after viewing the activity.

Take for credit

I wish to participate in this
activity and claim credit.

View without credit

I wish to view the activity
without claiming credit.

Educational Grants

An educational grant for this activity was provided by:


  1. Allos Therapeutics